Sorrento Therapeutics stock (US81803W1062): litigation update keeps troubled biotech in focus

Sorrento Therapeutics remains in the spotlight after a proposed settlement in ongoing litigation involving Virpax and Scilex, while the bankrupt biotech continues restructuring efforts. What investors should know about the complex situation around the former Nasdaq stock.

Sorrento Therapeutics has stayed on the radar of speculative biotech investors after new developments in its legal disputes, including a proposed settlement involving Virpax Pharmaceuticals and Scilex Pharmaceuticals announced on February 27, 2024, according to TMCnet as of 02/27/2024. The company has been navigating Chapter 11 restructuring and asset sales, and any legal resolution touching former subsidiaries attracts attention, as summarized by MarketBeat as of 03/01/2024.

As of: 19.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Sorrento Therapeutics
• Sector/industry: Biotechnology, therapeutics
• Headquarters/country: San Diego, United States
• Core markets: Oncology, pain management, infectious diseases
• Key revenue drivers: Drug candidates, licensing, subsidiaries and asset sales in restructuring
• Home exchange/listing venue: Previously Nasdaq (ticker: SRNE); delisted during Chapter 11 process
• Trading currency: US dollar (USD)

Sorrento Therapeutics: core business model

Sorrento Therapeutics built its business around discovering and developing therapies in oncology, pain management and immunology, leveraging antibody and cell-based platforms. Over the years, the pipeline featured monoclonal antibodies, antibody-drug conjugates and pain-relief formulations, with a strategy of advancing candidates into clinical trials while partnering or licensing where possible.

The company pursued a diversified platform approach, aiming to create value from multiple assets rather than a single flagship drug. It invested heavily in preclinical research and clinical development, which required substantial capital. This model is typical for clinical-stage biotech firms, where near-term revenue is limited and funding frequently comes from equity issuance, debt, and strategic collaborations.

In addition to internal R&D, Sorrento Therapeutics used subsidiaries and spin-outs to house specific assets, a structure designed to highlight distinct value propositions. For example, Scilex Pharmaceuticals focused on non-opioid pain management products, while other entities held oncology and antibody technologies. These structures could, in theory, enable targeted partnerships, joint ventures or sales.

However, the capital-intensive nature of the pipeline and market volatility challenged the sustainability of this approach. As competitive pressures in oncology and pain therapeutics increased, and as regulatory timelines stretched, the company was exposed to financing risk. Over time these pressures contributed to Sorrento Therapeutics entering Chapter 11 bankruptcy protection, a process that drastically reshaped its business model and future prospects.

Main revenue and product drivers for Sorrento Therapeutics

Historically, Sorrento Therapeutics generated most of its potential value from its development-stage pipeline and related intellectual property. The company’s oncology programs drew interest because cancer therapies can command premium pricing and attract strategic partners. Targeted antibodies and cell-therapy approaches were positioned within fast-growing segments of the biotech landscape, though success required strong clinical data and regulatory milestones.

Pain management represented another important pillar. Through Scilex, Sorrento Therapeutics was connected to non-opioid pain treatments that aimed to address the need for safer alternatives to traditional pain medicines. Such products can tap large addressable markets, especially in the United States, where chronic pain is widespread and regulators focus on reducing opioid use. Royalties, milestones and product sales from these assets were viewed as potential revenue streams.

Licensing and collaboration deals were critical to the model. By out-licensing selected assets or forming partnerships, Sorrento Therapeutics sought upfront payments, research funding and future royalties. In a best-case scenario, these deals would offset some R&D costs and provide validation for the technology platforms. However, the timing and size of such agreements are unpredictable, and dependence on them adds uncertainty.

During the restructuring phase, monetization shifted toward asset sales and settlements. Disposals of stakes in subsidiaries, licensing of IP and legal resolutions potentially offered cash to support creditors and ongoing operations. For existing and former shareholders, the value of these transactions depends heavily on bankruptcy proceedings and the distribution of proceeds, making the link between asset-level performance and equity value highly complex.

Industry trends and competitive position

Sorrento Therapeutics operated in an intensely competitive biotech environment, particularly in oncology and immunology, where large pharmaceutical companies and numerous smaller biotechs pursue similar targets. The rapid pace of innovation, combined with high trial failure rates, makes differentiation essential. Companies must show clear clinical benefit, safety advantages, or manufacturing efficiencies to stand out.

Within pain management, competition is also significant but shaped by changing prescribing practices and regulatory scrutiny in the United States. Non-opioid solutions have become a strategic priority for many firms, yet reimbursement dynamics and physician adoption can limit uptake. For a company like Sorrento Therapeutics, strong data and well-executed commercialization strategies via subsidiaries or partners are needed to convert scientific promise into sustainable sales.

Because Sorrento Therapeutics has been under Chapter 11 protection, its competitive position has shifted from pipeline racing to asset preservation and restructuring. Larger peers with stronger balance sheets may be better placed to bring similar technologies to market. At the same time, financially distressed biotech assets can become acquisition targets, potentially reshaping ownership of the underlying technologies and their role in the broader competitive landscape.

Why Sorrento Therapeutics matters for US investors

For US investors, Sorrento Therapeutics illustrates both the opportunity and risk profile of small and mid-cap biotech exposure. The company was previously listed on Nasdaq under the ticker SRNE, which made it accessible through mainstream brokerage accounts. Many domestic investors were attracted by its focus on cutting-edge therapies with large potential addressable markets, especially in oncology and non-opioid pain treatments.

The subsequent financial difficulties, delisting and Chapter 11 proceedings highlight how dependent such companies are on capital markets and clinical outcomes. When financing conditions tighten or trial results disappoint, equity holders can see rapid value erosion. This makes position sizing, diversification and careful review of regulatory filings particularly important in the biotech segment of US portfolios.

Even now, developments around litigation, settlements and asset sales are followed by US market participants because they can influence recovery prospects for different stakeholder groups. For investors tracking distressed and special-situations strategies, Sorrento Therapeutics offers a live case study of how intellectual property, subsidiaries and legal claims are untangled and potentially monetized in a complex restructuring process.

Conclusion

Sorrento Therapeutics has transitioned from a high-risk, high-reward biotech story into a complex restructuring and litigation case that continues to evolve. The proposed settlement involving Virpax and Scilex underscores how legacy relationships and subsidiaries remain relevant even after delisting and bankruptcy filings. For observers of the US biotech sector, the company’s trajectory illustrates how scientific ambition, capital structure and legal strategy intersect. Any assessment of potential value now requires careful attention to court documents, asset transactions and creditor negotiations, alongside the scientific status of remaining drug candidates.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.